Robert W. Baird Increases Definium Therapeutics (NASDAQ:DFTX) Price Target to $75.00

Key Points

• Robert W. Baird raised Definium Therapeutics’ price target to $75 from $57 and maintained an “outperform” rating, implying roughly 75% upside from the referenced $42.79 share price. Analysts overall assign the stock a “Buy” consensus with an average target of $58.38.
• Definium’s shares rose 4.6%, while the company’s latest quarterly loss of $1.44 per share significantly exceeded the expected loss of $0.55 per share, underscoring ongoing operating losses.
• Insiders sold 48,096 shares worth approximately $2.17 million over the past 90 days, while institutional investors and hedge funds own 27.91% of the company.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) had its price target boosted by analysts at Robert W. Baird from $57.00 to $75.00 in a research note issued to investors on Thursday,Benzinga reports. The firm presently has an "outperform" rating on the stock. Robert W. Baird's price objective indicates a potential upside of 75.27% from the company's current price.

DFTX has been the topic of several other research reports. Citigroup restated a "buy" rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Wells Fargo & Company initiated coverage on shares of Definium Therapeutics in a research note on Monday, July 27th. They set an "overweight" rating and a $68.00 target price on the stock. Piper Sandler restated an "overweight" rating and set a $75.00 target price (up from $73.00) on shares of Definium Therapeutics in a research report on Friday, August 7th. Canaccord Genuity Group set a $58.00 price target on Definium Therapeutics and gave the stock a "buy" rating in a report on Tuesday, June 30th. Finally, Stifel Nicolaus raised their price objective on Definium Therapeutics from $30.00 to $60.00 and gave the company a "buy" rating in a report on Wednesday, July 8th. Two research analysts have rated the stock with a Strong Buy rating, fifteen have given a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock has an average rating of "Buy" and a consensus target price of $58.38.

Definium Therapeutics Stock Up 4.6%

Shares of DFTX stock opened at $42.79 on Thursday. Definium Therapeutics has a twelve month low of $8.70 and a twelve month high of $49.70. The stock has a market cap of $4.27 billion, a P/E ratio of -12.48 and a beta of 2.23. The stock has a 50 day moving average of $39.06 and a 200 day moving average of $26.52. The company has a current ratio of 6.95, a quick ratio of 6.95 and a debt-to-equity ratio of 0.04.

Definium Therapeutics (NASDAQ:DFTX - Get Free Report) last issued its quarterly earnings data on Thursday, August 6th. The company reported ($1.44) EPS for the quarter, missing analysts' consensus estimates of ($0.55) by ($0.89). As a group, sell-side analysts expect that Definium Therapeutics will post -2.81 EPS for the current year.

Insider Activity

In other news, insider Mark Sullivan sold 13,008 shares of the stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $585,750.24. Following the completion of the transaction, the insider directly owned 320,571 shares in the company, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO Brandi Roberts sold 3,013 shares of the business's stock in a transaction that occurred on Thursday, June 25th. The shares were sold at an average price of $45.03, for a total transaction of $135,675.39. Following the completion of the sale, the chief financial officer directly owned 209,487 shares in the company, valued at $9,433,199.61. This trade represents a 1.42% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last 90 days, insiders sold 48,096 shares of company stock worth $2,165,763. 2.40% of the stock is owned by insiders.

Hedge Funds Weigh In On Definium Therapeutics

Several institutional investors have recently modified their holdings of the business. Russell Investments Group Ltd. increased its stake in Definium Therapeutics by 110.4% in the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company's stock valued at $25,000 after purchasing an additional 2,003 shares during the last quarter. BNP Paribas Financial Markets boosted its stake in Definium Therapeutics by 56.0% in the second quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company's stock valued at $55,000 after acquiring an additional 3,020 shares in the last quarter. Caxton Associates LLP purchased a new position in shares of Definium Therapeutics during the third quarter worth about $126,000. Mercer Global Advisors Inc. ADV grew its holdings in shares of Definium Therapeutics by 10.5% during the third quarter. Mercer Global Advisors Inc. ADV now owns 21,931 shares of the company's stock worth $259,000 after purchasing an additional 2,079 shares during the last quarter. Finally, Scientech Research LLC acquired a new stake in shares of Definium Therapeutics during the third quarter worth about $286,000. Institutional investors and hedge funds own 27.91% of the company's stock.

Key Headlines Impacting Definium Therapeutics

Here are the key news stories impacting Definium Therapeutics this week:

• Positive Sentiment: The Phase 3 Voyage study reportedly showed that DT120 reduced anxiety symptoms by 5.4 points more than placebo on the HAM-A scale, marking the second positive late-stage study highlighted by the company. Definium Says DT120 Phase 3 GAD Study Shows 5.4-Point HAM-A Benefit vs Placebo
• Positive Sentiment: Coverage characterized the results as a major success for Definium’s LSD-based psychiatric drug, driving a sharp advance in the stock and improving confidence in DT120’s prospects in GAD and another potential indication. Definium says LSD-based pill reduces anxiety in late-stage study
• Positive Sentiment: Needham raised its DFTX price target to $66 from $50 and maintained a Buy rating, implying substantial potential upside from the referenced $42.79 price. Investors may also be looking toward an additional September 2026 catalyst. Needham raises Definium Therapeutics price target
• Neutral Sentiment: Trading in DFTX was temporarily halted for pending news before the clinical announcement, reflecting the significance of the expected trial update rather than a change in the company’s fundamentals.
• Negative Sentiment: HC Wainwright reduced multiple EPS forecasts, including its FY2026 estimate to a $3.05 loss per share from $2.10 and its FY2027 estimate to a $1.71 loss from $1.22. The revisions highlight continued operating losses and execution risk despite the encouraging clinical data.

About Definium Therapeutics

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source